指南与共识慢阻肺

中国专家共识:肺癌抗体偶联药物治疗不良反应的多学科管理(2025版)

Consensus of Chinese experts on the multidisciplinary management of adverse reactions to antibody-drug conjugates in the treatment of lung cancer (2025 edition)
RSS 订阅 · 指南共识 · 慢阻肺 · 2026-06-22

该共识由中国老年保健协会胸部肿瘤精准治疗分会牵头,联合消化、皮肤、呼吸、眼科及肿瘤等多学科专家制定,基于肺癌领域现有抗体偶联药物(ADC)安全性数据,针对消化、血液、肝胆、肺、皮肤、眼、感觉神经及肌肉骨骼等系统不良反应,提出21条推荐,涵盖ADC治疗前安全评估、治疗期间综合监测与管理、患者教育及特殊人群用药指导。

要点

  • ADC常见不良反应涉及消化、血液、肝胆、肺、皮肤、眼、感觉神经及肌肉骨骼系统。
  • 晚期肺癌患者常合并慢阻肺和肺部炎症,增加ADC不良反应管理难度。
  • 共识提出21条推荐,覆盖ADC治疗前评估、治疗中监测及特殊人群用药。

核心结论

  • 共识旨在为临床医生提供ADC在肺癌中应用的实用指导,以最大化患者治疗获益。

研究设计与样本

  • 由中国老年保健协会胸部肿瘤精准治疗分会牵头,组织消化、皮肤、呼吸、眼科及肿瘤等多学科国内专家共同制定。

主要发现

  • ADC常见不良反应主要涉及消化系统、血液系统、肝胆系统、肺系统、皮肤、眼、感觉神经系统及肌肉骨骼系统。
  • 肺癌疾病亚型与分子病理机制复杂、治疗方式多样,且晚期患者常合并慢阻肺和肺部炎症,使ADC不良反应综合管理更具挑战。

关键数值与推荐

  • 共识共提出21条推荐,涵盖ADC治疗前安全评估、治疗期间相关不良反应的综合监测与管理、患者教育及特殊人群用药指导。

临床怎么用

  • 临床医生可依据共识推荐,在ADC治疗前进行安全评估、治疗期间综合监测与管理不良反应、开展患者教育并指导特殊人群用药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Zhonghua Zhong Liu Za Zhi. 2026 Jun 23;48(6):703-723. doi: 10.3760/cma.j.cn112152-20251113-00569. ABSTRACT Antibody-drug conjugates (ADCs) are covalently conjugated molecules composed of a monoclonal antibody, a payload, and a linker. They represent an innovative therapeutic approach that combines the precise targeting capability of target therapies with the cytotoxic effects of chemotherapeutic agents. Given the unique molecular structure of ADCs, drug-related adverse reactions have drawn a considerable attention. Based on the safety data of ADCs currently available in the field of lung cancer, the common adverse drug reactions primarily involve the digestive system, hematologic system, hepatobiliary system, pulmonary system, skin, eyes, sensory nervous system, and musculoskeletal system. Unlike other cancer types, lung cancer is characterized by complex disease subtypes and molecular pathological mechanisms, as well as diverse treatment modalities. Moreover, patients with advanced lung cancer often have comorbidities such as chronic obstructive pulmonary disease and pulmonary inflammation, making the comprehensive management of ADC-related adverse reactions even more challenging. To address this, the Precision Treatment Branch of Thoracic Oncology, Chinese Geriatric Health Association, has taken the lead in organizing a multidisciplinary panel of domestic experts in gastroenterology, dermatology, respiratory medicine, ophthalmology and oncology, to discuss and jointly formulate the "Consensus of Chinese experts on the multidisciplinary management of adverse reactions to antibody-drug conjugates in the treatment of Lung Cancer (2025 edition)". A total of 21 recommendations are proposed in this consensus, covering pre-ADC safety assessments, comprehensive monitoring and management of relevant adverse reactions during ADC treatment, patient education, and medication guidance for special populations. The consensus aims is to provide clinicians with practical guidelines for the application of ADC, thereby maximizing therapeutic benefits for patients with lung cancer. PMID: 42331546 | DOI: 10.3760/cma.j.cn112152-20251113-00569

来源:指南共识 · 慢阻肺,查看原文。版权归原作者所有。

引用

  1. 指南共识 · 慢阻肺:Consensus of Chinese experts on the multidisciplinary management of adverse reactions to antibody-drug conjugates in the treatment of lung cancer (2025 edition)

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。